Mississauga’s Nuvo Research, which has developed an osteoarthritis pain-killing cream that is absorbed through the skin, saw its revenues leap on a milestone payment. Upon receiving FDA approval, Nuvo received $15-million payment from its marketing partner, Covidien. Ultimately the Company received $27.3-million in a single quarter when licensing payments were added to the mix. Nuvo management has taken the approval to market of Pennsaid, the commercial name of the treatment, as a opportunity to diversify; last December they shuffled management around to put more resources behind the development of its autoimmune drug platform.
1. Price to Sales: 1.96
As of Friday, July 23 Nuvo had 417.30 million shares outstanding. The price, as of the same date, was $.185 This gave The Company a market capitalization of $77.2 million. In the trailing four quarters Nuvo posted sales of $39.23 million.
2. Cash to Market Cap: 47%
As of March 31st, 2010 Nuvo had a Cash and Short Term Investments position of $36.25 million. The Company’s Market Capitalization, as of Friday, July 23rd was $77.2 million.
3. Debt to Market Cap: 0.0004%
As of March 31st, 2010 Nuvo had a Long Term Debt position of $6,000. The Company’s Market Capitalization, as of Friday, July 23rd was $77.2 million.
4. Three Year Growth: 128.9%
Revenue was $4.07 million in FY 2006. This grew to $38.35 million in FY 2009.
5. Enterprise Value to Sales: 1.05 x Sales
Nuvo’s Enterprise Value is $41 million, based on a market capitalization of $77.2 million, plus Long Term Debt of $6,000, minus Cash and Short Term Investments of $36.25 million.
All financial information about Nuvo is gleaned from
their filings with the System for Electronic Document Analysis and
All calculations are based on The Company’s closing share price as of
close July 23rd, 2010: $.185
Sales from trailing four quarters: $77.2 million
Cash and Short Term Investments as of March 31st, 2010: $36.25 million
Shares outstanding: 417,308,012